GLI1 and neoplasm: Direct proof of GLI2 transcription factor binding to the Survivin promoter, promoter activity assays and Survivin downregulation upon Hh/GLI signaling inhibition by SMO inhibitor cyclopamine, or GLI inhibitor GANT61 identified Survivin as a transcriptional target of GLI2 in a variety of tumor cells of different origin as well as in a murine tumor model [9].